(Q28214774)

0 references

J Listing

0 references

A Zink

0 references

R Alten

0 references

W Golder

0 references

E Gromnica-Ihle

0 references

H Kellner

0 references

A Krause

0 references

M Schneider

0 references

H Sörensen

0 references

H Zeidler

0 references

W Thriene

0 references

J Sieper

Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors

0 references

language of work or name

English

0 references

publication date

6 April 2002

0 references

published in

The Lancet

0 references

volume

359

0 references

issue

9313

0 references

page(s)

1187-93

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908215-6

7 January 2021

Update: the twenty subtypes of HLA-B27.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908215-6

7 January 2021

Pathogenesis of spondylarthropathies. Persistent bacterial antigen, autoimmunity, or both?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908215-6

7 January 2021

Enthesitis and ankylosis in spondyloarthropathy: what is the target of the immune response?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908215-6

7 January 2021

Radiologic diagnosis and pathology of the spondyloarthropathies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908215-6

7 January 2021

Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908215-6

7 January 2021

Prognosis, course of disease, and treatment of the spondyloarthropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908215-6

7 January 2021

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908215-6

7 January 2021

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908215-6

7 January 2021

Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908215-6

7 January 2021

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908215-6

7 January 2021

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908215-6

7 January 2021

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908215-6

7 January 2021

Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908215-6

7 January 2021

Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908215-6

7 January 2021

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908215-6

7 January 2021

Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908215-6

7 January 2021

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908215-6

7 January 2021

The bath ankylosing spondylitis radiology index (BASRI): A new, validated approach to disease assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908215-6

7 January 2021

Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908215-6

7 January 2021

Infliximab treatment of severe ankylosing spondylitis: one-year followup

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908215-6

7 January 2021

Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908215-6

7 January 2021

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908215-6

7 January 2021

10.1016/S0140-6736(02)08215-6

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

11955536

1 reference

Consolidated OpenCitations Corpus – April 2017